Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

"Creating a Favorable Micro-Environment for Fat Grafting in a Novel Model of Radiation Induced Mammary Fat Pad Fibrosis."

Truong JL, Liu M, Tolg C, Barr M, Dai C, Raissi TC, Wong E, DeLyzer T, Yazdani A, Turley EA.

Plast Reconstr Surg. 2019 Sep 30. doi: 10.1097/PRS.0000000000006344. [Epub ahead of print]

PMID:
31577661
2.

Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.

Yang J, Price MA, Wanshura LEC, He J, Yi M, Welch DR, Li G, Conner S, Sachs J, Turley EA, McCarthy JB.

Melanoma Res. 2019 Aug;29(4):365-375. doi: 10.1097/CMR.0000000000000574.

PMID:
31140988
3.

Corrigendum: Hyaluronan, Cancer-Associated Fibroblasts and the Tumor Microenvironment in Malignant Progression.

McCarthy JB, El-Ashry D, Turley EA.

Front Cell Dev Biol. 2018 Sep 24;6:112. doi: 10.3389/fcell.2018.00112. eCollection 2018.

4.

Spatial statistical tools for genome-wide mutation cluster detection under a microarray probe sampling system.

Luo B, Edge AK, Tolg C, Turley EA, Dean CB, Hill KA, Kulperger RJ.

PLoS One. 2018 Sep 25;13(9):e0204156. doi: 10.1371/journal.pone.0204156. eCollection 2018.

5.

A truncated RHAMM protein for discovering novel therapeutic peptides.

Hauser-Kawaguchi A, Tolg C, Peart T, Milne M, Turley EA, Luyt LG.

Bioorg Med Chem. 2018 Oct 1;26(18):5194-5203. doi: 10.1016/j.bmc.2018.09.018. Epub 2018 Sep 18.

PMID:
30249497
6.

Hyaluronan, Cancer-Associated Fibroblasts and the Tumor Microenvironment in Malignant Progression.

McCarthy JB, El-Ashry D, Turley EA.

Front Cell Dev Biol. 2018 May 8;6:48. doi: 10.3389/fcell.2018.00048. eCollection 2018. Review. Erratum in: Front Cell Dev Biol. 2018 Sep 24;6:112.

7.

Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level.

Klank RL, Decker Grunke SA, Bangasser BL, Forster CL, Price MA, Odde TJ, SantaCruz KS, Rosenfeld SS, Canoll P, Turley EA, McCarthy JB, Ohlfest JR, Odde DJ.

Cell Rep. 2017 Apr 18;19(3):668. doi: 10.1016/j.celrep.2017.03.074. No abstract available.

8.

Hyaluronan modulates growth factor induced mammary gland branching in a size dependent manner.

Tolg C, Yuan H, Flynn SM, Basu K, Ma J, Tse KCK, Kowalska B, Vulkanesku D, Cowman MK, McCarthy JB, Turley EA.

Matrix Biol. 2017 Nov;63:117-132. doi: 10.1016/j.matbio.2017.02.003. Epub 2017 Feb 21.

PMID:
28232112
9.

Receptor for hyaluronan mediated motility (RHAMM/HMMR) is a novel target for promoting subcutaneous adipogenesis.

Bahrami SB, Tolg C, Peart T, Symonette C, Veiseh M, Umoh JU, Holdsworth DW, McCarthy JB, Luyt LG, Bissell MJ, Yazdani A, Turley EA.

Integr Biol (Camb). 2017 Mar 1;9(3):223-237. doi: 10.1039/c7ib00002b. Epub 2017 Feb 20.

10.

Biphasic Dependence of Glioma Survival and Cell Migration on CD44 Expression Level.

Klank RL, Decker Grunke SA, Bangasser BL, Forster CL, Price MA, Odde TJ, SantaCruz KS, Rosenfeld SS, Canoll P, Turley EA, McCarthy JB, Ohlfest JR, Odde DJ.

Cell Rep. 2017 Jan 3;18(1):23-31. doi: 10.1016/j.celrep.2016.12.024. Erratum in: Cell Rep. 2017 Apr 18;19(3):668.

11.

RB Loss Promotes Prostate Cancer Metastasis.

Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, Dean JL, Snook A, McNair C, Price M, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turley EA, Pienta KJ, Feng FY, Dicker AP, Knudsen KE, Den RB.

Cancer Res. 2017 Feb 15;77(4):982-995. doi: 10.1158/0008-5472.CAN-16-1589. Epub 2016 Dec 6.

12.

Carcinoma Cell Hyaluronan as a "Portable" Cancerized Prometastatic Microenvironment.

Turley EA, Wood DK, McCarthy JB.

Cancer Res. 2016 May 1;76(9):2507-12. doi: 10.1158/0008-5472.CAN-15-3114. Epub 2016 Apr 20. Review.

13.

Can CD44 Be a Mediator of Cell Destruction? The Challenge of Type 1 Diabetes.

Assayag-Asherie N, Sever D, Bogdani M, Johnson P, Weiss T, Ginzberg A, Perles S, Weiss L, Sebban LE, Turley EA, Okon E, Raz I, Naor D.

PLoS One. 2015 Dec 1;10(12):e0143589. doi: 10.1371/journal.pone.0143589. eCollection 2015.

14.

Identification, design and synthesis of tubulin-derived peptides as novel hyaluronan mimetic ligands for the receptor for hyaluronan-mediated motility (RHAMM/HMMR).

Esguerra KV, Tolg C, Akentieva N, Price M, Cho CF, Lewis JD, McCarthy JB, Turley EA, Luyt LG.

Integr Biol (Camb). 2015 Dec;7(12):1547-60. doi: 10.1039/c5ib00222b. Epub 2015 Oct 12.

15.

Hyaluronan, Inflammation, and Breast Cancer Progression.

Schwertfeger KL, Cowman MK, Telmer PG, Turley EA, McCarthy JB.

Front Immunol. 2015 Jun 8;6:236. doi: 10.3389/fimmu.2015.00236. eCollection 2015. Review.

16.

The Content and Size of Hyaluronan in Biological Fluids and Tissues.

Cowman MK, Lee HG, Schwertfeger KL, McCarthy JB, Turley EA.

Front Immunol. 2015 Jun 2;6:261. doi: 10.3389/fimmu.2015.00261. eCollection 2015. Review.

17.

Hyaluronan-phosphatidylethanolamine polymers form pericellular coats on keratinocytes and promote basal keratinocyte proliferation.

Symonette CJ, Kaur Mann A, Tan XC, Tolg C, Ma J, Perera F, Yazdani A, Turley EA.

Biomed Res Int. 2014;2014:727459. doi: 10.1155/2014/727459. Epub 2014 Sep 9.

18.

Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis.

Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, Hague MN, Ablack A, Carmine-Simmen K, McPherson VA, Postenka CO, Turley EA, Courtneidge SA, Chambers AF, Lewis JD.

Cell Rep. 2014 Sep 11;8(5):1558-70. doi: 10.1016/j.celrep.2014.07.050. Epub 2014 Aug 28.

19.

Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues.

Tolg C, McCarthy JB, Yazdani A, Turley EA.

Biomed Res Int. 2014;2014:103923. doi: 10.1155/2014/103923. Epub 2014 Aug 4. Review.

20.

Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset.

Veiseh M, Kwon DH, Borowsky AD, Tolg C, Leong HS, Lewis JD, Turley EA, Bissell MJ.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1731-9. doi: 10.1073/pnas.1402383111. Epub 2014 Apr 14.

21.

Evaluation of protein biomarkers of prostate cancer aggressiveness.

Rizzardi AE, Rosener NK, Koopmeiners JS, Isaksson Vogel R, Metzger GJ, Forster CL, Marston LO, Tiffany JR, McCarthy JB, Turley EA, Warlick CA, Henriksen JC, Schmechel SC.

BMC Cancer. 2014 Apr 5;14:244. doi: 10.1186/1471-2407-14-244.

22.

Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors.

Rizzardi AE, Vogel RI, Koopmeiners JS, Forster CL, Marston LO, Rosener NK, Akentieva N, Price MA, Metzger GJ, Warlick CA, Henriksen JC, Turley EA, McCarthy JB, Schmechel SC.

Cancer. 2014 Jun 15;120(12):1800-9. doi: 10.1002/cncr.28646. Epub 2014 Mar 25.

23.

Oral administration of hyaluronan reduces bone turnover in ovariectomized rats.

Ma J, Granton PV, Holdsworth DW, Turley EA.

J Agric Food Chem. 2013 Jan 16;61(2):339-45. doi: 10.1021/jf300651d. Epub 2013 Jan 8.

PMID:
23256527
24.

A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds.

Tolg C, Hamilton SR, Zalinska E, McCulloch L, Amin R, Akentieva N, Winnik F, Savani R, Bagli DJ, Luyt LG, Cowman MK, McCarthy JB, Turley EA.

Am J Pathol. 2012 Oct;181(4):1250-70. doi: 10.1016/j.ajpath.2012.06.036. Epub 2012 Aug 11.

25.

RHAMM and CD44 peptides-analytic tools and potential drugs.

Turley EA, Naor D.

Front Biosci (Landmark Ed). 2012 Jan 1;17:1775-94. Review.

PMID:
22201835
26.

Imaging of homeostatic, neoplastic, and injured tissues by HA-based probes.

Veiseh M, Breadner D, Ma J, Akentieva N, Savani RC, Harrison R, Mikilus D, Collis L, Gustafson S, Lee TY, Koropatnick J, Luyt LG, Bissell MJ, Turley EA.

Biomacromolecules. 2012 Jan 9;13(1):12-22. doi: 10.1021/bm201143c. Epub 2011 Dec 12.

27.

CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.

Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA, McCarthy JB.

Pigment Cell Melanoma Res. 2011 Dec;24(6):1148-57. doi: 10.1111/j.1755-148X.2011.00929.x. Review.

28.

How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression?

Telmer PG, Tolg C, McCarthy JB, Turley EA.

Commun Integr Biol. 2011 Mar;4(2):182-5. doi: 10.4161/cib.4.2.14270.

29.

Hyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer.

Veiseh M, Turley EA.

Integr Biol (Camb). 2011 Apr;3(4):304-15. doi: 10.1039/c0ib00096e. Epub 2011 Jan 24. Review.

PMID:
21264398
30.

Rapid in vivo whole body composition of rats using cone beam ╬╝CT.

Granton PV, Norley CJ, Umoh J, Turley EA, Frier BC, Noble EG, Holdsworth DW.

J Appl Physiol (1985). 2010 Oct;109(4):1162-9. doi: 10.1152/japplphysiol.00016.2010. Epub 2010 Aug 5.

31.

RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity.

Tolg C, Hamilton SR, Morningstar L, Zhang J, Zhang S, Esguerra KV, Telmer PG, Luyt LG, Harrison R, McCarthy JB, Turley EA.

J Biol Chem. 2010 Aug 20;285(34):26461-74. doi: 10.1074/jbc.M110.121491. Epub 2010 Jun 17.

32.

Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.

Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB.

Cancer Res. 2009 Oct 1;69(19):7538-47. doi: 10.1158/0008-5472.CAN-08-4626. Epub 2009 Sep 8.

33.

Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?

Turley EA, Veiseh M, Radisky DC, Bissell MJ.

Nat Clin Pract Oncol. 2008 May;5(5):280-90. doi: 10.1038/ncponc1089. Epub 2008 Mar 18.

34.

CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice.

Naor D, Nedvetzki S, Walmsley M, Yayon A, Turley EA, Golan I, Caspi D, Sebban LE, Zick Y, Garin T, Karussis D, Assayag-Asherie N, Raz I, Weiss L, Slavin S, Golan I.

Ann N Y Acad Sci. 2007 Sep;1110:233-47. Review.

PMID:
17911438
35.

The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.

Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J, Turley EA.

J Biol Chem. 2007 Jun 1;282(22):16667-80. Epub 2007 Mar 28.

36.

Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair.

Tolg C, Hamilton SR, Nakrieko KA, Kooshesh F, Walton P, McCarthy JB, Bissell MJ, Turley EA.

J Cell Biol. 2006 Dec 18;175(6):1017-28. Epub 2006 Dec 11.

37.

Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy.

Cook AC, Chambers AF, Turley EA, Tuck AB.

J Biol Chem. 2006 Aug 25;281(34):24381-9. Epub 2006 Jun 28.

38.

The mechanism of molecular redundancy in autoimmune inflammation in the context of CD44 deficiency.

Naor D, Nedvetzki S, Assayag N, Thurmond RL, Huang JF, Turley EA.

Ann N Y Acad Sci. 2005 Jun;1050:52-63. Review.

PMID:
16014520
39.

RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy.

Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, Huang JF, Neudecker BA, Wang FS, Turley EA, Naor D.

Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18081-6. Epub 2004 Dec 13. Erratum in: Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1263. Wang, Fu-Shang [corrected to Wang, Fu-Sheng].

40.
41.

Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.

Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, Bissell MJ.

J Natl Cancer Inst. 2002 Oct 2;94(19):1494-503.

42.

Peptides that mimic glycosaminoglycans: high-affinity ligands for a hyaluronan binding domain.

Ziebell MR, Zhao ZG, Luo B, Luo Y, Turley EA, Prestwich GD.

Chem Biol. 2001 Nov;8(11):1081-94.

43.

Signaling properties of hyaluronan receptors.

Turley EA, Noble PW, Bourguignon LY.

J Biol Chem. 2002 Feb 15;277(7):4589-92. Epub 2001 Nov 20. Review. No abstract available.

44.

Hyaluronan and homeostasis: a balancing act.

Tammi MI, Day AJ, Turley EA.

J Biol Chem. 2002 Feb 15;277(7):4581-4. Epub 2001 Nov 20. Review. No abstract available.

45.

Active erk regulates microtubule stability in H-ras-transformed cells.

Harrison RE, Turley EA.

Neoplasia. 2001 Sep-Oct;3(5):385-94.

46.

Identification of sequence, protein isoforms, and distribution of the hyaluronan-binding protein RHAMM in adult and developing rat brain.

Lynn BD, Li X, Cattini PA, Turley EA, Nagy JI.

J Comp Neurol. 2001 Oct 22;439(3):315-30.

PMID:
11596057
47.
48.

Fibroblasts require protein kinase C activation to respond to hyaluronan with increased locomotion.

Hall CL, Collis LA, Bo A J, Lange L, McNicol A, Gerrard JM, Turley EA.

Matrix Biol. 2001 Jun;20(3):183-92.

PMID:
11420150
49.

Extracellular matrix remodeling: multiple paradigms in vascular disease.

Turley EA.

Circ Res. 2001 Jan 19;88(1):2-4. No abstract available.

PMID:
11139464
50.

Receptor for hyaluronan-mediated motility (RHAMM), a hyaladherin that regulates cell responses to growth factors.

Cheung WF, Cruz TF, Turley EA.

Biochem Soc Trans. 1999 Feb;27(2):135-42. Review. No abstract available.

PMID:
10093722

Supplemental Content

Loading ...
Support Center